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Peripheral immune tolerance requires a controlled balance between the maintenance of
self-tolerance and the capacity to engage protective immune responses against pathogens.
Dendritic cells (DCs) serve as sentinels of the immune system by sensing environmental
and inﬂammatory signals, and play an essential role in the maintenance of immune toler-
ance.To achieve this, DC play a key role in dictating the outcome of immune responses by
inﬂuencing the balance between inﬂammatory or Foxp3+ regulatoryT (Treg) cell responses.
At the heart of this immunological balance is a ﬁnely regulated DC and Treg cell crosstalk
whereby Treg cells modulate DC phenotype and function, and DC drive the differentiation
of Foxp3+ Treg cells in order to control immune responses.This review will focus on recent
advances, which highlight the importance of this bidirectional DC and Treg cell crosstalk
during the induction of tolerance and organ-speciﬁc autoimmunity. More speciﬁcally, we
will discuss how Treg cells modulate DC function for the suppression of inﬂammatory
responses and how DC subsets employ diverse mechanisms to drive differentiation ofTreg
cells. Finally, we will discuss the therapeutic potential of tolerogenic DCs for the induction
of tolerance in autoimmune diseases.
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INTRODUCTION
Immune tolerance consists of two main processes, namely cen-
tral and peripheral tolerance. Central tolerance takes place in the
thymus where most of the self-reactive T cells are deleted at an
immature stage of their development (Bluestone, 2011). Despite
negative selection, self-reactive T cells can escape thymic clonal
deletion, and subsequently provoke autoimmune diseases such as
type 1 diabetes (T1D), multiple sclerosis (MS), and inﬂammatory
bowel disease (IBD) unless they are controlled by one of many
peripheral mechanisms (Sakaguchi et al., 1995).
REGULATORY T CELLS ARE MAJOR MEDIATORS OF
PERIPHERAL SELF-TOLERANCE
In order to ensure tolerance induction of such auto-reactive T cells
in the peripheral immune system, a number of mechanisms
including a network of regulatory T (Treg) cells exist to achieve
this function. Treg cells constitute 1–10% of thymic and periph-
eral CD4+ T cells in humans and mice, and arise during a thymic
selection (Sakaguchi, 2000). They are characterized by the consti-
tutive expression of the IL-2Rα chain (CD25) and expression of
the forkhead winged helix transcriptional regulator Foxp3 (Hori
et al., 2003). The importance of Foxp3 has been demonstrated
by natural mutations of the foxp3 gene that result in a loss of
Treg cell function and the development of severe autoimmune
diseases, including T1D, in scurfy mice and IPEX patients (Ben-
nett et al., 2001; Chang et al., 2006; d’Hennezel et al., 2009). Treg
cell population can be divided into the naturally occurring Foxp3
Treg population (here deﬁned as Treg), generated in the thymus
and anyone of many inducible Treg cell populations (here deﬁned
as iTreg), that are derived in the periphery from CD4+Foxp3−
precursors upon activation in presence of differentiating signals
like TGF-β and IL-10 (e.g. Th3, Tr1 cells) (Haribhai et al., 2011;
Pot et al., 2011).
DENDRITIC CELLS DICTATE THE BALANCE BETWEEN
TOLERANCE AND IMMUNITY
Numerous studies show that different cell populations of the
innate immune system such as dendritic cells (DCs),macrophages,
natural killer cells, and γδ T cells can regulate tolerance induction
(Lehuen et al., 2010). DCs represent a heterogeneous population
of bone marrow-derived cells and are the most potent antigen
presenting cells (APCs) (Banchereau and Steinman, 1998; Short-
man and Naik, 2007). DCs are derived from multiple lineages,
have a distinct stage of development, activation, and maturation
state (Banchereau and Steinman, 1998; Steinman et al., 2003).
DCs exist as a distinct subset and differ in their ontogeny, sur-
face molecule expression, and biological functions (Banchereau
and Steinman, 1998; Steinman and Nussenzweig, 2002). These
factors seems to determine the T cells polarizing signals and type
T cells responses induced by DCs namely Th1, Th2, Th17, or
Treg cells. Although all DCs are able to prime T cells, they dif-
fer in their in vivo niches, migration, function, and requirements
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from the environment for their generation and activation (Short-
man and Naik, 2007). DCs are divided into conventional, myeloid,
or plasmacytoid DC (pDC) subsets. In mice, three main sub-
sets of conventional CD11chi DCs have been identiﬁed in the
spleen and lymph nodes, namely the CD8+, CD4+CD8−, and
CD4−CD8−DCs (Vremec et al., 2000). Lymph nodes contain two
additional DCs subsets; skin-derived Langerhans cells and tis-
sue interstitial DCs that arrive from the periphery through the
lymphatic circulation (Vremec et al., 2000).
Dendritic cells receive the maturation signals through the
pathogen associated molecular patterns (PAMPs) and damage
associated molecular patterns (DAMPs) receptors that detect cer-
tain microbial and tissue damage signals via activation of nuclear
factor-κB (NF-κB) and interferon regulatory factors (IRF) fami-
lies (Maldonado and von Andrian, 2010). Upon activation, DCs
up-regulate a wide variety of gene products involved in antigen
presentation and co-stimulation such as MHC II, CD86, CD80,
OX40-L, inducible co-stimulator (ICOS) ligand as well cytokines
involved in the modulation of effector function such as IL-1β,
IL-2, IL-6, IL-8, IL-12, and IL-18 (Maldonado and von Andrian,
2010). These changes are required for DCs to initiate a three-step
T cell activation process: MHC molecules displaying cognate pep-
tide (signal 1), co-stimulatory signal expression (signal 2), and
cytokine production by DCs (signal 3).
While potently capable to initiate inﬂammatory responses, DCs
also play an important role in modulating tolerance induction.
TolerogenicDCs are characterized by high antigen uptake and pro-
cessing capabilities in order to present antigen to antigen-speciﬁc
T cells, but fail to deliver proper co-stimulatory signal for effector
T (Teff) cells activation and proliferation (Steinman et al., 2003).
This results in T cell death, T cell anergy, or induction and expan-
sion of Treg cells subsets. As such, tolerogenic DCs have been
shown to suppress experimental autoimmune disease and play an
important role in alloimmunity (Morelli and Thomson, 2007).
SUBSETS OF TOLEROGENIC DCs: DIVISION OF LABOR IN
TOLERANCE INDUCTION
DifferentDCs subsets are specialized in tolerance vs. inﬂammatory
immune response decisions. Speciﬁc markers capable of discrim-
inating tolerogenic from inﬂammatory DCs are still ill-deﬁned.
However,CD8+ DCs expressingCD95LandDEC205oftenpossess
tolerogenic properties (Mahnke et al., 2002; Yamazaki et al., 2008).
Expression of inhibitory immunoglobulin-like transcript (ILT)
receptors is also frequently observed in some subsets of tolero-
genicDCs,where ILT-3 and ILT-4mediated signals onDCs inhibits
expression of co-stimulatory molecules and induce a tolerogenic
state (Manicassamy and Pulendran, 2011). In humans, ILT-3 and
ILT-4 expressing tolerogenic DCs can promote antigen-speciﬁc
unresponsiveness in CD4+ T cells and induce Treg cells. Recent
studies have shown that Indoleamine 2,3-dioxygenase (IDO) and
IL-10 can induce the expression of ILT-3 and ILT-4 on DCs
and promote tolerogenic response (Manavalan et al., 2003). Acti-
vation of ILT-3 receptor on DCs leads to the recruitment of
protein phosphate SHP-1 and SHIP-1 to the immunoreceptor
tyrosine-based inhibitory motif (ITIM) resulting in the inhi-
bition of NF-κB and p38MAPK pathways that are critical for
inﬂammatory responses (Cella et al., 1997; Svajger et al., 2008).
While immature DCs appear to be good indicators for DC tolero-
genicity, mature DCs might not always induce immunity. Hence,
other factors such as exposure to certain differentiation signals
or cues from the local environment might condition DCs beyond
their expression of co-stimulatory molecules. Therefore, toler-
ance is not only a consequence of T cells receiving insufﬁcient
signals 2 and 3, but additional tolerance inducing factors might
be in play.
GENERATION OF TOLEROGENIC DCs
Treg CELLS, THROUGH VARIOUS MECHANISMS, PROMOTE
THE GENERATION OF TOLEROGENIC DCs
While several environmental factors and cytokines can promote
the tolerogenic phenotype of DCs, there is accumulating evidence
that Treg cells can also induce a tolerogenic phenotype in DCs by
modulating their maturation and function. Several studies indi-
cate that Treg cells can suppress the capacity of DCs to activate
Teff cells by down-regulating CD80/CD86 expression on bone
marrow-derived or splenic DCs in vitro (Cederbom et al., 2000).
Depletion of Treg cells from asthma susceptible mice resulted in
DCs with higher expression levels of MHC II, CD80, CD86 and
displayed a increased T cell stimulatory activity (Mahnke et al.,
2007). Although the mechanism by which Treg cells achieve this is
unknown, this might be mediated through cell surface molecules
or cytokines such as IL-10, CTLA-4, and TGF-β (Figure 1).
Role of Treg cell-derived IL-10 in induction of tolerogenic DCs
The production and activity of the immunomodulatory cytokine
IL-10 is often associated with tolerogenic responses. IL-10
inhibits multiple aspects of DC function including MHCI/II and
CD80/CD86 co-stimulatory molecules expression and a release
of pro-inﬂammatory cytokines such as IL-1β, IL-6, TNF-α, and
IL-12 (Mahnke et al., 2002, 2007; Alexander, 2005). Interestingly,
IL-10 mediated effects could be only observed when immature
DCs were exposed to IL-10 (Read et al., 2000), as mature DCs
were insensitive to IL-10 stimulation and displayed stable, mature
phenotype (Read et al., 2000). In addition, DCs cultured in pres-
ence of Treg cells has been shown to secrete of IL-10, TGF-β,
and IL-27 cytokines (Awasthi et al., 2007). IL-27 cytokine plays
an important role in suppressing production of Th17 polariz-
ing cytokines, such as IL-1β, IL-6, IL-23 derived from DCs and
act on naïve T cells to induce Tr1 differentiation (Pot et al.,
2009). IL-10 treated DCs have also been shown to promote
tumor growth, andprevent transplant rejection andameliorateMS
(Mahnke et al., 2007).
CTLA-4 is a potent inducer of tolerogenic DCs
CTLA-4 plays an important role in Treg cell-mediated suppres-
sion (Salomon et al., 2000). Treg cells constitutively express high
levels of CTLA-4 and conditional deﬁciency of CTLA-4 in Treg
cells results in lymphoproliferation and variety of autoimmune
disease, an outcome analogous to global CTLA-4 deﬁcient mice
(Wing et al., 2008). Monoclonal antibody blockade of CTLA-4
exacerbates T1D in non-obese diabetic (NOD) mice and induce
IBD (Read et al., 2000; Wing and Sakaguchi, 2010). CTLA-4 medi-
ates suppression through down regulation of CD80 and CD86
expression on DCs. Treg cells from CTLA-4 deﬁcient mice or
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FIGURE 1 | Major mechanisms by whichTreg cells induce tolerogenic
DCs and inhibitTeff cell activation.Treg cells can inhibit the function of
DCs through various mechanisms. CTLA-4 expression onTreg cells
down-regulates up-regulation of CD80 and CD86 co-stimulatory molecules
on DCs. LAG3 binding to MHCII-expressing immature DCs results in
inhibitory signals that suppress DCs maturation and co-stimulatory capacity.
Nrp-1 expression onTreg cells promotes sustained interactions between
Treg cells and DCs, and limits the access of Teff cells to DCs. Expression
of LFA-1 onTreg cells, promotes aggregate formation around DCs,
and inhibit the up-regulation of CD80 and CD86 on DCs. IL-10 inhibits
up-regulation of MHCI/II and B7 co-stimulatory molecule expression,
suppresses release of pro-inﬂammatory cytokines such as IL-1β, IL-6,
TNF-α, and IL-12, and up-regulates of B7-H4 and B7-H inhibitory
molecules.
FIGURE 2 | Major mechanisms of immune modulation by tolerogenic
DCs. DCs modulate the immune system by promotingTreg cell generation
through various mechanisms. Upon stimulation, DCs are able to increase
production of various cytokines and inﬂammatory mediators such as IL-10,
RA, vitamin D, TGF-β, IL-2, IL-10, TSLP, TNF-α and down-regulate expression
of inﬂammatory cytokines such as IL-12p70. DCs, by down-regulating
co-stimulation and antigen presentation, can favor induction of Treg cells.
Various signaling pathways program DCs to induce tolerogenic responses.
Activation of β-catenin signaling pathway promotes induction of
anti-inﬂammatory factors such as vitamin A and is important for promoting
Treg cell induction and limiting inﬂammatory responses. TSLPR signaling
inhibits activation of STAT4 and IRF-8, factors critical for production of theTh1
polarizing factor IL-12. Triggering of DCs throughTLR2-6 leads to Erk activation
which mediates induction of RALDH and conversion of retinal to RA. TLR9
ligation can drive induction of IDO in DCs limiting IL-6 production and
differentiation of Th17 cells while inducing differentiation of Treg cells.
administration of CTLA-4 blocking antibodies results in reduced
down-modulation of B7 molecules and increased T cells prolifera-
tion (Oderup et al., 2006). IDO, a potent regulatory molecule that
is know to induce the production of pro-apoptotic metabolites
from the catabolism of tryptophan, results in the suppression of
Teff cells through a mechanism dependent on interaction between
CTLA-4 and CD80/CD86 (Fallarino et al., 2003; Baban et al.,
2009). Baban et al. (2009) recently demonstrated that IDO is a
critical molecular switch that stimulates potent Treg cells sup-
pression while simultaneously block IL-6 driven reprogramming
of Treg cells into Th17 cells and production pro-inﬂammatory
cytokines such as IL-17, IFN-γ, TNF-α, and IL-2. Interestingly,
it has also been demonstrated that Treg cells can modulate DCs
to express IDO and more speciﬁcally CTLA-4 immunoglobulin
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fusion protein was found to induce IDO expression through lig-
ation to CD80 and CD86 molecules in mouse and human DCs
(Fallarino et al., 2003; Mellor and Munn, 2004; Mellor et al., 2004).
In addition, IL-10 produced by Treg cells is critical for sustain-
ing IDO expression in DCs (Manicassamy and Pulendran, 2011).
Thus, IDO is one of the molecular switches controlling the balance
between Treg and Teff cell responses.
B7-H4 and B7-H: B7 family members that negatively regulate
T cell immunity
A number of other mechanisms have been proposed by which
Treg cells can either abrogate the antigen presenting capacity of
DCs or promote the secretion immunomodulatory cytokines.
For example, Treg cells are able to induce the expression of B7-H
and B7-H4, a ligands responsible for negative regulation of cell-
mediated immunity in peripheral tissues (Mahnke et al., 2007).
Recently, Treg cells have also been shown to trigger high levels of
IL-10 production byAPCs and in turn stimulate B7-H4 expression
in an autocrine fashion and render these APCs immunosuppres-
sive (Kryczek et al., 2006).
Lymphocyte activation gene 3 (LAG3)
Lymphocyte activation gene 3 is cell surface molecule expressed on
Treg cells that can modulate DC phenotype and function (Huang
et al., 2004; Workman and Vignali, 2005; Liang et al., 2008). LAG3
is a CD4 homolog that binds MHC II molecules with very high
afﬁnity, has a negative regulatory intrinsic function and is required
for maximal Treg cells suppression (Huang et al., 2004; Work-
man and Vignali, 2005). Binding of LAG3 to MHC II molecules
on immature DCs initiates a receptor tyrosine-based activation
motif (ITAM) mediated inhibitor signaling pathway that sup-
press DC maturation (Liang et al., 2008). These ﬁndings provide
a novel tolerogenic pathway that may endow Treg cells to enhance
tolerance by inhibiting DCs functions.
Treg–DCs cognate interactions mechanism
It has been shown that Treg cells are more motile that naïve T
cells in vitro, in turn out-competing the latter for physical access
to DCs (Tran et al., 2009). This Treg–DC cell aggregation pro-
cess is antigen-dependent, and the selective advantage of Treg
cells over Teff cells for physical interactions with DCs can be
attributed, at least in part, to the expression of LFA-1 (Lympho-
cyte function-associated antigen 1) by Treg cells, as deﬁciency or
blockade of LFA-1 abolishes this process. By forming aggregates,
Treg cells inhibit the up-regulation of CD80, CD86 on immature
DCs and also down-regulate the expression of CD80 and CD86
by mature DCs without affecting the expression of CD40 or MHC
II molecules (Onishi et al., 2008). This modiﬁcation of CD80 and
CD86 is CTLA-4 dependent as Treg cells from CTLA-4 deﬁcient
mice fail to modify expression of CD80 and CD86 (Onishi et al.,
2008). Therefore at least in vitro, Treg cell contact dependent sup-
pression can be dissected by two consequent steps; initial LFA-1
dependent formation of aggregates around immature DCs and
subsequent LFA-1 and CTLA-4 dependent active down-regulation
of CD80 and CD86 expression (Onishi et al., 2008). Overall, this
results in down-regulation of Teff cell activation and induction
of immune suppression and tolerance. The signiﬁcance of DCs
and Treg cells interaction has been also demonstrated in studies
using NOD mice. The Bluestone group, by means of intravital
microscopy, demonstrated that direct interactions between Treg
cells and DCs in vivo resulted in inhibition of Teff cells activation
(Tadokoro et al., 2006; Tang et al., 2006) suggesting a potential
feedback loop between Treg cells and DCs. In this model, Treg
cells up-regulate LFA-1 expression upon activation by immature
DCs, adhere to DCs, and suppress the expression of CD86 and
CD80, in turn inhibiting the activation and expansion of Teff cells
(Sakaguchi et al., 2009). While Foxp3+ Treg must be activated by
antigen in order to exert their suppressive functions in vitro and
in vivo (Takahashi et al., 1998), activated Foxp3+ Treg cells can
mediate in vitro bystander suppression of Teff cells with different
antigen speciﬁcities. However, it still remains to be determined
whether such mechanism can also apply to other cell types like
DCs, and towhat extent such bystander suppression occurs in vivo.
Recently it has been shown that neuropilin (Nrp-1) also plays a
critical role in mediating Treg–DC interactions (Sarris et al., 2008).
Nrp-1 is a ligand binding receptor for a class of semaphorins,
and is preferentially expressed by Treg cells. Nrp-1 expression can
be induced by ectopic expression of Foxp3 in Foxp3− T cells,
and antibody blockade of Nrp-1 reduces the frequency of Treg–
DCs interactions. Furthermore, retroviral introduction of Nrp-1
endows T helper cells with ability to establish a long interactions
with DCs (Sarris et al., 2008). Interestingly, it has been demon-
strated that Nrp-1 can confer a high adhesive property of Treg cells
in their interaction with DCs under steady conditions; however,
this potential by Treg cells is lost under inﬂammatory conditions
(Sarris et al., 2008).
The results described above demonstrate the capacity of
Foxp3+ Treg cells, through the expression of LAG3 and Nrp-1
molecules, to inﬂuence immature but not mature DCs. Mature
DCs, in contrast to immature DCs, produce pro-inﬂammatory
cytokines such as IL-6, TNF-α, and IL-1βwhich candown-regulate
Foxp3 expression and abolish Foxp3+ Treg cell-mediated suppres-
sion (Rutella et al., 2006). Although IL-6 production induced by
LPS stimulation only slightly reduced Foxp3+ Treg cells-mediated
suppression, DC-derived IL-6 may render responder T cells resis-
tant to suppression (Pasare and Medzhitov, 2003). Moreover, IL-6
might also facilitate the reprogramming of Foxp3+ Treg cells into
Th17 lineage (Bettelli et al., 2007).
In other instances, it has been demonstrated that Treg cells,
through the expression of LFA-1 and CTLA-4, can suppress TNF
and LPS maturated DCs by selectively down-regulating CD80,
CD86, PDL1, and PDL2, but not MHCII and CD40, expression on
the DC surface. Overall, these ﬁndings demonstrate that Treg cells
may employ speciﬁc mechanism(s) to suppress DCs functions in
different microenvironments of antigen priming.
THE GUT ENVIRONMENT PROMOTES DEVELOPMENT
OF TOLEROGENIC DCs
The identiﬁcation of tolerogenic DCs subsets in microenviron-
ments such as gut, skin, and lungs suggest that local signals induce
tolerogenic DCs in situ. Given the enormous amount of microbial
stimuli in the gut, intestinal DCs represent a key regulatory mech-
anism to prevent excessive inﬂammation. Speciﬁcally, CD11c+
DCs expressing CD103 have been identiﬁed in the gut-associated
lymphoid tissue (GALT) and mesenteric lymph node with the
Frontiers in Immunology | Antigen Presenting Cell Biology June 2012 | Volume 3 | Article 165 | 4
“ﬁmmu-03-00165” — 2012/6/21 — 10:22 — page 5 — #5
Kornete and Piccirillo DC-Treg crosstalk in immune tolerance
specialized function of inducing Foxp3+ Treg cells and maintain-
ing gut immune homeostasis (Coombes et al., 2007; Sun et al.,
2007). This CD11c+ DC subset expresses high levels of CD103,
MHC II, CD80, and CD86. Interestingly, absence of CD103 on
DCs led to the abrogation of Treg cell activity indicating a cru-
cial role for CD103 in maintaining the balance between Treg
and Teff cells (Annacker et al., 2005). While mesenteric lymph
node derived CD103+ DCs are prone to imprint expression of
CCR9 on T cells, an important homing receptor enabling hom-
ing to the gut, CD103− DCs promote the differentiation of
CD4+ T cells producing IFN-γ (Jaensson et al., 2008). Collec-
tively, CD103+ and CD103− DCs represent functional subsets
and CD103 is critical to regulate Teff and Treg cells in the gut
(Annacker et al., 2005).
APOPTOTIC DCs FAVOR FORMATION OF TOLEROGENIC DCs
Recent studies show that immature DCs can uptake apoptotic
and necrotic DCs without being recognized as an inﬂammatory
event (Kushwah et al., 2010). This uptake results in conversion of
mature DCs into tolerogenic DCs that remain resistant to LPS
induced maturation and induces the production of TGF-β via
the mTOR signaling pathway (Kushwah et al., 2010). TGF-β pro-
ducing DCs subsequently interact with naïve T cells and drive
the differentiation of iTreg cells (Kushwah et al., 2010; Kushwah
and Hu, 2011). Moreover, recent studies showed that α-CD3
mAb treatment transiently depletes large numbers of T cells
and induce long term immune tolerance (Perruche et al., 2008;
Esplugues et al., 2011). The mechanism underlying this regulatory
outcome is due to increased production of TGF-β by immature
DCs after engulfment of apoptotic T cells (Perruche et al., 2008).
A recent study demonstrated that α-CD3 mAb treatment resulted
in elimination of the inﬂammatory Th17 cells from intestinal
lumen or resulted in acquisition Th17 cells producing a IL-10
(Esplugues et al., 2011). However, it is not known which spe-
ciﬁc subset of gut-residing DCs is responsible for production of
TGF-β and induction of IL-10 producing Th17 cells with regula-
tory capacity.
IMMUNE MODULATION BY TOLEROGENIC DCs
DC EMPLOYS VARIOUS MECHANISMS TO DRIVE THE
DIFFERENTIATION OF Treg CELLS
B7 co-stimulatory molecules promote differentiation of Treg cells
In the steady state, DCs are largely immature and present anti-
gens to T cells in tolerogenic manner. Such DCs are characterized
by low expression of CD80, CD86, and CD40 (Steinman and
Nussenzweig, 2002; Steinman et al., 2003; Hubert et al., 2007).
Moreover, targeting of antigens to immature DCs via the regu-
latory receptor DEC205 results in tolerance through deletion of
antigen-speciﬁc T cells and preferential induction of Treg cells
(Hawiger et al., 2001). Interestingly, antibodies bound to DEC205
are efﬁciently internalized and delivered to antigen processing
compartments, however internalization of the antigen by DEC205
does not induce the maturation of the DCs (Mahnke et al., 2000).
Immature DCs had been shown to induce Treg cells in vitro and
anti-DEC205 targeting of antigens to immature DCs led to aner-
gic T cells in vivo (Mahnke et al., 2003). These data show that
that the DEC205 receptor is critical for DCs in the steady state
to promote tolerance (Mahnke et al., 2003). Moreover, treatment
with respective anti-DEC antigen conjugates results in signiﬁ-
cant improvement of autoimmune disorders such as T1D and
MS (Hawiger et al., 2004; Bruder et al., 2005). DCs can also
favor tolerance by utilizing ICOS, another CD28 family mem-
ber, to speciﬁcally drive Tr1 cell differentiation (Akbari et al., 2002;
Ito et al., 2007).
Despite the established role of immature DCs as inducers of
Treg cells, recent studies have shown that mature DCs, express-
ing high levels of CD86, also have the potential to preferentially
expandTreg cells in vitro, andpreventT1Ddevelopment (Yamazaki
et al., 2003; Tarbell et al., 2004; Sgouroudis et al., 2011). Interest-
ingly, DCs isolated from Peyer’s patches, eye, or lungs display
a mature phenotype, secrete IL-10, but not IL-12 and drive
the development of Tr1 cells (Akbari et al., 2001). Thus, sig-
nals derived from the local tissue environment might play a role
in conditioning tolerogenic DCs and drive the differentiation of
Treg cells. All together, these ﬁndings suggest that the previously
established paradigm whereby immature DCs leads to Treg cell
differentiation and mature DCs drive Teff cell responses might be
revisited (Figure 2).
DC-DERIVED CYTOKINES THAT DRIVES DIFFERENTIATION
OF Treg CELLS
IL-10
Dendritic cells can secrete high amounts of IL-10 upon stimula-
tion and drive differentiation of naïve T cells into IL-10 secreting
Tr1 cells (Kushwah and Hu, 2011). DCs of IL-10 transgenic
mice display a particularly immature phenotype and Tr1 cells are
signiﬁcantly enriched in spleens of these mice (Wakkach et al.,
2003). Langerhans cells in the skin also produce IL-10 and drive
differentiation of Tr1 cells (Igyarto et al., 2009).
TNF-α
TNF-α can also induce tolerogenic state in DCs (Menges et al.,
2002; Mahnke et al., 2007). Despite the fact that TNF-α treated
DCs has a mature phenotype, they fail to secrete inﬂamma-
tory cytokines such as IL-1β, IL-6, TNF-α, and IL-12 (Menges
et al., 2002). Moreover, these tolerogenic DCs were able to
reverse development of EAE where their suppressive effects
were mediated by the induction of IL-10 producing Treg cells
(Mahnke et al., 2007). However, there is also a controversial data
demonstrating that TNF-α blockade prevented DC maturation
and Treg cells were induced in the absence of TNF-α (Mahnke
et al., 2007).
TGF-β
TGF-β-producing DCs might preferentially drive differentiation
of Treg cells rather than Teff cells. Tumor-bearing mice contains
a CD11c+ DC subset characterized by low expression of CD80
and CD86 co-stimulatory molecules and are endowed with the
capacity to secrete TGF-βwhich promotes Treg cells differentiation
and proliferation in vivo (Ghiringhelli et al., 2005).
IL-2
We and others have shown that a local deﬁciency in islets of
IL-2, a critical cytokine for the homeostasis/ﬁtness of Treg cells
in vivo, compromises Treg cell function in islets, a defect readily
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corrected by lowdose IL-2 therapy inNODmice. NODmice intro-
gressed with a protective IL2 allelic variant from T1D-resistant
C57BL6 mice (NOD.Idd3BL6) are resistant to autoimmune dia-
betes in contrast to wild-type NOD mice which are susceptible to
the disease. Moreover, T1D-protective IL2 allelic variants in NOD
mice impinge T1D development by bolstering IL-2 production
by CD4+ Teff cells in turn, driving the expansion and homeosta-
sis of CD4+Foxp3+ Treg cells in islets. Recently, we showed that
CD11c+ DCs in NOD.Idd3BL6 have an increased maturation sta-
tus relative to wild-type NOD CD11c+ DCs. We also showed that
NOD.Idd3BL6 DCs are more potent activators of Treg cells func-
tions in vitro and in vivo, and this increased capacity of congenic
DCs to prime Treg cells is attributed to their ability to produce
IL-2. Consistently, IL-2 blockade in vitro completely abolished
the proliferative advantage conferred by Idd3BL6 DCs on Foxp3+
Treg cells (Sgouroudis et al., 2011). Interestingly,CD11c+ MHCII+
DCs isolated from pancreatic LN of NOD.Idd3BL6 mice promoted
Foxp3+Treg cells expansion more efﬁciently that WT DCs isolated
from similar sites, suggesting that Idd3BL6 DCs display tolerogenic
phenotype speciﬁcally in the pancreatic sites to enhance Foxp3+
Treg cells functions (Sgouroudis et al., 2011). Thus, T1D-protective
IL2 allelic variants impinge the development of β-islet autoimmu-
nity by bolstering IL-2 mRNA expression and protein secretion by
CD4+ Teff cells and DC and in turn, driving the functional home-
ostasis of CD4+Foxp3+ Treg cells in the target organ (Sgouroudis
et al., 2011).
It has been previously shown that CD40/CD40L interaction
regulates Treg cells homeostasis (Kumanogoh et al., 2001; Guiducci
et al., 2005). MatureDCs lackingCD40L are impaired in sustaining
Treg cells proliferation and survival. The underlying mechanism
is mediated by fact that CD40L deﬁcient DCs are not able to pro-
duce IL-2, to as similar extent as wild-type DCs. Administration of
rhIL-2 in vivo restored Treg cells numbers in thymic and peripheral
compartments of CD40L deﬁcient mice, by increasing survival
and homeostatic proliferation of Treg cells (Kumanogoh et al.,
2001; Guiducci et al., 2005). Therefore, CD40 triggering by Treg
cells contributes to induce IL-2 through CD40L on DCs needed
for their maintenance. Therefore, several mechanisms have been
established by DCs in order to maintain a peripheral pool of Treg
cells through IL-2 production (Kumanogoh et al., 2001; Guiducci
et al., 2005).
IDO EXPRESSION BY DCs DRIVES Treg CELLS DIFFERENTIATION
Dendritic cells populations expressing IDO play a critical role in
immune tolerance by promoting iTreg cells differentiation (Mellor
and Munn, 2004; Matteoli et al., 2010). IDO expression by DCs
appears to be dependent on Aryl hydrocarbon receptor (AHR)
as DCs lacking AHR fail to up-regulate IDO and prime T cells
responses rather than tolerance induction (Nguyen et al., 2010).
Selective inhibition or genetic deletion of IDO affects the devel-
opment of antigen-speciﬁc Treg cells while promotes Th1 and
Th17 development and worsens T cells mediated and dextrin
sulfate sodium (DSS) colitis in mice (Matteoli et al., 2010). It
has been shown that TLR9 ligation can drive induction of IDO
in pDCs that subsequently suppress IL-6 production and differ-
entiation of Th17 cells while induce differentiation of Treg cells
(Baban et al., 2009).
SITE SPECIFIC RESIDING DCs SUPPORTS Treg CELLS DIFFERENTIATION
Thymic residential DCs play a role in induction
of Foxp3+ Treg cells
It has been shown that DCs and medullary thymic epithelial cells
(mTECs) contribute to the selection of Foxp3+ Treg cells in the
thymus. Epithelial cells in Hassall’s corpuscles in the thymus pro-
duce thymic stromal lymphopoietin (TSLP) which subsequently
acts on thymic DCs by binding to TSLP receptor (TSLPR) and IL-
7Rα complex and drives induction of CD80 and CD86 (Ziegler
and Liu, 2006). These DCs subsequently drive differentiation
of CD4+CD8+CD25− thymocytes into Foxp3+Treg cells, which
highly depend from IL-2 and CD28 signaling (Ziegler and Liu,
2006). These data demonstrate that TSLP activated myeloid DCs
are critical for selection of self-reactive thymocytes to develop
into Foxp3+ Treg cells. In addition to the myeloid DCs, human
thymic pDCs can also induce differentiation of Treg cells in a
CD40L-dependant fashion (Hanabuchi et al., 2010; Martin-Gayo
et al., 2010). Thymic pDCs express TSLPR along with IL-7Rα
and are responsive to TSLP derived from thymic epithelial cells
(Hanabuchi et al., 2010; Martin-Gayo et al., 2010). More evidence
for the contribution of thymic DCs in Treg cell induction comes
from studies done in mouse models, where targeting of neo-
self antigens to thymic DCs instructed antigen-speciﬁc T cells
to develop into Foxp3+ Treg cells (Proietto et al., 2008). Three
thymic DCs subtypes, namely conventional DCs, thymus resident
DCs, and pDCs were shown to be able of instructing Foxp3+ Treg
cells differentiation in vitro, supporting the model where antigen
recognition on thymic DCs can directly elicit Foxp3+ Treg cells
differentiation (Wu and Shortman, 2005).
Gut-residing DCs maintain Treg cell stability via production
of retinoic acid and TGF-β
Dendritic cells from the lamina propria of the small intestine
preferentially promote Treg cell induction relative to the DCs of
lymphoid organs. This increased induction of Treg cells has been
shown to be dependent on TGF-β and retinoic acid (RA), a vita-
min A metabolite highly expressed in small intestine (Coombes
et al., 2007; Sun et al., 2007; Belkaid and Oldenhove, 2008). DCs
are the major subset of immune cells able of metabolizing vitamin
A to RA. RA synthesis is a highly regulated process that involves
several key enzymes: vitamin A is oxidized to retinaldehyde by
alcohol dehydrogenase and then to RA by retinal dehydroge-
nase (RALDH). Manicassamy et al. (2009) and Manicassamy and
Pulendran (2011) demonstrated that TLR2 and TLR6 signaling
by zymosine promote induction of RALDH1 and RALDH2 in
DCs via ERK dependent mechanism. This result in conversion of
retinal to RA which then exerts an autocrine effect on DCs via
RA receptor to induce SOCS3, this then suppress activation of
p38MAPK and pro-inﬂammatory cytokines. Accumulating evi-
dence shows that RA directly inﬂuences the development and
function of various immune cells. For example, RA promotes the
differentiation of Treg cells and suppress differentiation of Th1 and
Th17 cells, and prevents IBD and EAE in mice (Kushwah and Hu,
2011). CD103+ DCs in the intestine lamina propria and mesen-
teric lymphnodes express high levels of RALDHandhave ability to
induce Foxp3+ Treg cells. It is well documented IL-6 is an essential
cytokine driving Th17 cell differentiation, while down-regulate
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Foxp3 expression in Treg cells. Interestingly, Zhou et al. (2010)
showed that RA maintains the stability of Foxp3+ Treg cells and
sustains their suppressive potential in the presence of IL-6, through
down-regulation of IL-6 receptor expression and signaling, there-
fore preventing Treg cells conversion into Th17 cells (Coombes and
Powrie, 2008; Zhou et al., 2010). CD103+ DCs from the lamina
propria of the small intestine and mesenteric lymph node have
been shown to be signiﬁcantly better than splenic DCs at medi-
ating the conversion of naïve T cells into Foxp3+ T cells in the
presence of exogenous TGF-β (Coombes et al., 2007). Moreover,
expression of the αvβ8 integrin by DCs is important for TGF-β
activation, accumulation of Treg cells in the small intestine and
prevention of colitis development (Coombes and Powrie, 2008).
Overall, gut-derived signals may condition DCs to produce TGF-β
for Treg cell generation.
β Catenin: a novel regulator of intestinal homeostasis
Wnt-β-catenin signaling in intestinal DCs regulates the bal-
ance between inﬂammatory and regulatory responses. Recently,
Manicassamy et al. (2009) performed a gene expression proﬁle of
lamina propria DCs and demonstrated that several Wnt family
genes and β-catenin were constitutively expressed by intesti-
nal DCs, but not by splenic DCs (Manicassamy et al., 2009).
Furthermore, they showed that β-catenin signaling promotes the
induction of Treg cells while suppress Th1 andTh17 cells in the gut,
indicating that β-catenin expression by intestinal DCs is impor-
tant for maintaining the balance between Treg and Teff cells in the
gut (Manicassamy et al., 2010). In addition, intestinal DCs lacking
β-catenin expression produced lower levels of Treg cell-promoting
stimuli including RA metabolizing enzymes, IL-10, and TGF-β,
but higher levels of Th17-promoting cytokines IL-23 and IL-6
(Manicassamy et al., 2010). Overall, β-catenin signaling is needed
to maintain intestinal homeostasis through the induction of Treg
cells and the suppression of pro-inﬂammatory factors.
The gut microenvironment inﬂuences intestinal DC function
Many of the unique properties of intestinal DCs appear to be a
result of environmental conditioning. Activation of NF-κB expres-
sion in intestinal epithelial cells, perhaps as a result of microﬂora
signaling through PRRs, enhances TSLP production (Coombes
and Powrie, 2008). Recently, important role for TSLP in dictat-
ing the quality of immune response has been suggested. TSLP
and other epithelial cells factors limits the activation of STAT4
and IRF-8, essential factors for the production of Th1 polariz-
ing cytokine IL-12-23p40 (Arima et al., 2010). In addition, TSLP
signaling also induce the activation of STAT6, which programs
DCs to secrete chemokines necessary for the recruitment of Th2
cells, and increase IL-10 and TGF-β production (Coombes and
Powrie,2008;Arima et al.,2010). TSLPhas alsobeen shown to con-
fer human thymic DCs with ability to induce the differentiation
of CD4+CD25− thymocytes into Foxp3+CD4+CD25+Treg cells
(Watanabe et al., 2005). Thus, the increased ability of gut-residing
CD103+ DCs to induce Foxp3 may be due to TSLP.
Overall, these ﬁndings illustrate that the intestinal immune
system (i.e., GALT) is a preferential site for the induction of Treg
cells, and provides a mechanism by which the thymus-derived
Treg cell pool could be complemented by de novo generated Treg
cells for the efﬁcient control of inﬂammatory responses toward
speciﬁc commensal bacteria and food antigens (Coombes and
Powrie, 2008).
The skin and lung are naturally tolerogenic environments
Like the intestine, the skin and lungs are also constantly exposed
to various microbes and environmental antigens such as aller-
gens. The interaction between vitamin D and RANK–RANKL
signaling pathway in the skin plays a role in DC-mediated iTreg
cells induction (Loser et al., 2006; Kushwah and Hu, 2011). This
process occurs via the activated metabolite of vitamin D, VD3,
which exerts its actions through its nuclear receptor, VDR. VDR is
expressed on DCs and vitamin D treatment inhibits DCs matura-
tion and their ability to prime alloreactive T cells responses (Loser
et al., 2006). Similarly to the intestine, lung CD103+ DCs pro-
mote the induction of Treg cells, while the CD103− DCs represent
the main producers of pro-inﬂammatory cytokines in response
to airborne allergens and TLR ligands. In contrast to lung and
mucosal sites, CD103−CD11b+ migratory dermalDCs, compared
toCD103+CD11b+ DCs, aremuchmorepotent inpromotingTreg
cells induction (Guilliams et al., 2010; Pulendran et al., 2010).
THERAPEUTIC APPLICATIONS OF TOLEROGENIC DCs
The possibility to generate or expand tolerogenic DCs in vitro pro-
vides signiﬁcant opportunities for therapeutic interventions. DCs
are generated in vitro from bone marrow precursors in rodents
or blood monocytes in humans and can be rendered tolero-
genic by modulating their culture conditions through exposure to
cytokines, growth factors or pharmacologic mediators, or genetic
engineering (Morelli and Thomson, 2007). In vitro generation
of tolerogenic DC can be achieved through exposure to various
anti-inﬂammatory agents such as vitamin D, as well as clinically
approved suppressive drugs such as corticosteroids, cyclosporin,
and rapamycin (Morelli and Thomson, 2007). Rapamycin acts as
an inhibitor of the Akt–mTOR pathway, increases the number
of Foxp3+ Treg cells, and promotes their resistance to apoptosis
(Strauss et al., 2007; Basu et al., 2008). Moreover, rapamycin-
conditioned myeloid DCs fail to produce IL-12p70 and TNF-α
and are resistant to maturation induced by TLR ligands or by
CD40 signaling (Turnquist et al., 2007). Advances in gene trans-
fer technology offers the possibility to generate tolerogenic DCs
by genetically inducing the expression of immunosuppressive
molecules like IL-10, TGF-β, or CTLA-4, or blocking the expres-
sion of co-stimulatory molecules (Morelli and Thomson, 2007).
Conversely, it is possible to generate tolerogenic DCs in vitro that
drive Treg cells differentiation in a tissue speciﬁc manner in order
to inhibit inﬂammation in a particular site (Rescigno, 2010). For
example, intestinal epithelial cells release factors that drive the
development of mucosal like tolerogenic DCs (Iliev et al., 2007).
Incubation of DCs with intestinal, but not mammary or epithelial
cell-derived supernatants induces the expression of CD103onDCs
while inhibiting the secretion of inﬂammatory cytokines. These
in vitro generated CD103+ DCs can drive the induction of Treg
cells and expression of the gut-associated homing receptor α4β7
(Iliev et al., 2009). Moreover, only intestinal epithelial cells condi-
tioned DCs are able to protect against colitis development (Iliev
et al., 2009). Therefore, DCs conditioned at local environment are
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important for generation of Treg cells that are able to suppress and
home to speciﬁc sites.
CONCLUSION
Our understanding of the functional and phenotypic plastic-
ity of DCs, as well the capacity to modulate DCs development
and maturation in vitro and in vivo gives opportunity to use
these cells for therapeutic purpose in autoimmunity and cancer.
Tolerogenic DCs has a dual role, for example in cancer, a pro-
found defect in DCs function are associated with accumulation of
immature DCs in tumors where DCs are unable to initiate anti-
tumor immune responses while contributes to the recruitment,
expansion and function of Treg cells. While this have negative
outcome in cancer settings, similar scenario would be helpful in
the case of autoimmunity. Several studies in mice suggest that
DCs might be used in the treatment of autoimmunity through
their ability to induce Treg cells. For example, repetitive injec-
tions of semi-mature DCs results in protection from EAE and
thyroiditis (Ueno et al., 2007). In the NOD mice, DC-mediated
in vitro generation of Treg cells can inhibit spontaneous T1D
development in these mice (Ueno et al., 2007). In recent years,
several mechanisms have been identiﬁed to explain how tolero-
genic DCs mediate their function. For example, IDO expression
by intestinal DCs is important for regulating intestinal immune
homeostasis by keeping the balance between Treg cells and Th17,
Th1 cells. Deregulations of IDOactivity results in increased intesti-
nal inﬂammation, suggesting that IDO could be regarded as a
new target for IBD. Therefore, pharmacological targeting of IDO
during the chronic inﬂammation like IBD would be beneﬁcial
in dampening the inﬂammatory process and tissue damage in
the gut (Matteoli et al., 2010). Moreover, as IL-6 is often present
in inﬂammatory inﬁltrates in autoimmune settings, recent ﬁnd-
ings about ability of RA to stabilize Treg cells in the presence of
IL-6 offers the possibility that RA treated Treg cells can be used
in many autoimmune settings where achieve such a balance is
essential.
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